tiprankstipranks
Trending News
More News >
Advanced Enzyme Technologies Ltd (IN:ADVENZYMES)
:ADVENZYMES
India Market
Advertisement

Advanced Enzyme Technologies Ltd (ADVENZYMES) AI Stock Analysis

Compare
1 Followers

Top Page

IN:ADVENZYMES

Advanced Enzyme Technologies Ltd

(ADVENZYMES)

Select Model
Select Model
Select Model
Neutral 69 (OpenAI - 4o)
Rating:69Neutral
Price Target:
₹358.00
▲(11.89% Upside)
Advanced Enzyme Technologies Ltd has a strong financial foundation with consistent growth and solid margins, contributing significantly to the overall score. However, technical indicators suggest potential short-term weakness, and the valuation appears high, which tempers the overall score.

Advanced Enzyme Technologies Ltd (ADVENZYMES) vs. iShares MSCI India ETF (INDA)

Advanced Enzyme Technologies Ltd Business Overview & Revenue Model

Company DescriptionAdvanced Enzyme Technologies Limited researches and develops, manufactures, and markets enzymes and probiotics in India, the United States, Asia, Europe, and internationally. The company offers enzymes for human healthcare and animal nutrition, fruit and vegetable processing, baking, brewing, and malting, and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications. It also provides non-food processing enzymes for textile processing, leather, pulp and paper, detergents and cleaning aids, bio-fuels, and biocatalysis. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is based in Thane, India.
How the Company Makes MoneyADVENZYMES makes money primarily through the sale of its enzyme products to various industries such as pharmaceuticals, food and beverage, animal nutrition, and textiles. The company generates revenue by offering tailored enzyme solutions that enhance efficiency, reduce costs, and improve product quality for its clients. Key revenue streams include direct sales to manufacturers and processors, contract manufacturing, and strategic partnerships with industry leaders to co-develop new enzyme applications. The company also invests in research and development to innovate and expand its product portfolio, which in turn drives additional revenues and strengthens its market position. Strategic partnerships and collaborations with global and regional players further augment its earnings by expanding market reach and facilitating entry into new markets.

Advanced Enzyme Technologies Ltd Financial Statement Overview

Summary
Advanced Enzyme Technologies Ltd demonstrates a strong financial position with consistent revenue and profit growth, solid profit margins, and effective leverage management. The slight decline in EBIT margin and modest free cash flow growth present areas for improvement, but the company remains financially sound with minimal risk.
Income Statement
85
Very Positive
Advanced Enzyme Technologies Ltd shows a strong income statement with consistent revenue growth, evidenced by a 6.8% increase in the latest year. The company maintains high profit margins, with a net profit margin of over 20% and a gross profit margin around 48%. However, the slight decline in EBIT margin suggests efficiency improvements are needed. Overall, the company is financially healthy with robust profitability.
Balance Sheet
80
Positive
The balance sheet indicates a solid financial structure with a low debt-to-equity ratio of 0.03, showcasing strong leverage management. The equity ratio stands at a stable 87.6%, indicating reliance on equity financing. The return on equity is healthy at 9.2%, though slightly lower than industry leaders. Overall, the company displays a stable and conservative balance sheet with minimal financial risk.
Cash Flow
78
Positive
The cash flow statement reflects robust operating cash flows with a steady growth trend. The free cash flow to net income ratio is favorable, indicating efficient cash generation relative to earnings. However, the free cash flow growth rate has been modest. The company manages its capital expenditures prudently, but could enhance free cash flow growth further.
BreakdownTTMDec 2025Dec 2023Dec 2022Dec 2022Dec 2021
Income Statement
Total Revenue6.28B6.37B6.23B5.29B5.41B5.00B
Gross Profit4.01B3.07B2.46B4.09B4.09B3.95B
EBITDA2.23B2.27B2.27B2.09B1.79B2.41B
Net Income1.33B1.31B1.33B1.20B1.06B1.46B
Balance Sheet
Total Assets0.0016.21B15.35B12.68B14.22B11.53B
Cash, Cash Equivalents and Short-Term Investments5.07B5.88B5.48B3.74B4.86B3.17B
Total Debt0.00393.50M473.08M347.30M334.99M276.15M
Total Liabilities-13.89B1.53B1.64B1.27B1.38B1.22B
Stockholders Equity13.89B14.21B13.24B10.89B12.35B9.71B
Cash Flow
Free Cash Flow0.001.15B940.56M941.15M1.02B1.43B
Operating Cash Flow0.001.49B1.41B1.22B1.40B1.63B
Investing Cash Flow0.00-990.44M-646.49M-249.12M-2.98B-260.33M
Financing Cash Flow0.00-692.02M-507.06M-273.75M-257.98M-263.10M

Advanced Enzyme Technologies Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price319.95
Price Trends
50DMA
329.05
Negative
100DMA
320.94
Negative
200DMA
315.06
Positive
Market Momentum
MACD
0.70
Positive
RSI
38.78
Neutral
STOCH
10.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ADVENZYMES, the sentiment is Negative. The current price of 319.95 is below the 20-day moving average (MA) of 338.36, below the 50-day MA of 329.05, and above the 200-day MA of 315.06, indicating a neutral trend. The MACD of 0.70 indicates Positive momentum. The RSI at 38.78 is Neutral, neither overbought nor oversold. The STOCH value of 10.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ADVENZYMES.

Advanced Enzyme Technologies Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
₹35.80B26.151.64%5.89%-1.30%
67
Neutral
26.78B28.6810.21%0.41%2.12%-25.99%
58
Neutral
43.98B42.200.06%19.85%
57
Neutral
35.81B57.8811.59%0.03%2.37%-30.78%
54
Neutral
47.66B159.443.11%12.33%439.46%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:ADVENZYMES
Advanced Enzyme Technologies Ltd
319.95
-173.94
-35.22%
IN:DCAL
Dishman Carbogen Amcis Ltd.
280.50
100.50
55.83%
IN:GUFICBIO
Gufic Biosciences Limited
357.10
-28.24
-7.33%
IN:MOREPENLAB
Morepen Laboratories Limited
48.87
-36.31
-42.63%
IN:RPGLIFE
RPG Life Sciences Limited
2,303.35
-27.39
-1.18%
IN:SEQUENT
Sequent Scientific Limited
189.40
-43.10
-18.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 26, 2025